Overview

The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
A preliminary study to determine the safety and efficacy of intravitreal aflibercept injection in patients with persistent central serous chorioretinopathy.
Phase:
Phase 2
Details
Lead Sponsor:
Wills Eye
Collaborator:
Regeneron Pharmaceuticals
Treatments:
Aflibercept